Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Roger L Williams

Showing results (111-120 of 127) with videos related to

Pageof 13
Sort By:
Cell Reports|February 26, 2023
Molecular basis for differential activation of p101 and p84 complexes of PI3Kγ by Ras and GPCRsManoj K Rathinaswamy, Meredith L Jenkins, Benjamin R Duewell, et al.
Journal of Medicinal Chemistry|August 23, 2017
5-(4,6-Dimorpholino-1,3,5-triazin-2-yl)-4-(trifluoromethyl)pyridin-2-amine (PQR309), a Potent, Brain-Penetrant, Orally Bioavailable, Pan-Class I PI3K/mTOR Inhibitor as Clinical Candidate in OncologyFlorent Beaufils, Natasa Cmiljanovic, Vladimir Cmiljanovic, et al.
Nature Communications|March 11, 2021
Structural basis for VPS34 kinase activation by Rab1 and Rab5 on membranesShirley Tremel, Yohei Ohashi, Dustin R Morado, et al.
Nature Communications|March 10, 2017
Deconvolution of Buparlisib's mechanism of action defines specific PI3K and tubulin inhibitors for therapeutic interventionThomas Bohnacker, Andrea E Prota, Florent Beaufils, et al.
Oncogene|September 13, 2024
Multifocal, multiphenotypic tumours arising from an MTOR mutation acquired in early embryogenesisClarissa N Pacyna, Madhanagopal Anandapadamanaban, Kevin W Loudon, et al.
Nature Chemical Biology|September 15, 2022
Development of selective inhibitors of phosphatidylinositol 3-kinase C2αWen-Ting Lo, Hassane Belabed, Murat Kücükdisli, et al.
The Biochemical Journal|November 1, 2024
ATP-competitive inhibitors of PI3K enzymes demonstrate an isoform selective dual action by controlling membrane bindingGrace Q Gong, Glenn R Masson, Woo-Jeong Lee, et al.
Nature|August 6, 2013
Vesicular and non-vesicular transport feed distinct glycosylation pathways in the GolgiGiovanni D'Angelo, Takefumi Uemura, Chia-Chen Chuang, et al.
Science Signaling|December 6, 2012
G protein-coupled receptor-mediated activation of p110β by Gβγ is required for cellular transformation and invasivenessHashem A Dbouk, Oscar Vadas, Aliaksei Shymanets, et al.
Nature Communications|September 27, 2019
Human PI3Kγ deficiency and its microbiota-dependent mouse model reveal immunodeficiency and tissue immunopathologyAndrew J Takeda, Timothy J Maher, Yu Zhang, et al.
Pageof 13

Showing results (111-120 of 127) with videos related to

Sort By:
Pageof 13
Cell Reports|February 26, 2023
Molecular basis for differential activation of p101 and p84 complexes of PI3Kγ by Ras and GPCRsManoj K Rathinaswamy, Meredith L Jenkins, Benjamin R Duewell, et al.
Journal of Medicinal Chemistry|August 23, 2017
5-(4,6-Dimorpholino-1,3,5-triazin-2-yl)-4-(trifluoromethyl)pyridin-2-amine (PQR309), a Potent, Brain-Penetrant, Orally Bioavailable, Pan-Class I PI3K/mTOR Inhibitor as Clinical Candidate in OncologyFlorent Beaufils, Natasa Cmiljanovic, Vladimir Cmiljanovic, et al.
Nature Communications|March 11, 2021
Structural basis for VPS34 kinase activation by Rab1 and Rab5 on membranesShirley Tremel, Yohei Ohashi, Dustin R Morado, et al.
Nature Communications|March 10, 2017
Deconvolution of Buparlisib's mechanism of action defines specific PI3K and tubulin inhibitors for therapeutic interventionThomas Bohnacker, Andrea E Prota, Florent Beaufils, et al.
Oncogene|September 13, 2024
Multifocal, multiphenotypic tumours arising from an MTOR mutation acquired in early embryogenesisClarissa N Pacyna, Madhanagopal Anandapadamanaban, Kevin W Loudon, et al.
Nature Chemical Biology|September 15, 2022
Development of selective inhibitors of phosphatidylinositol 3-kinase C2αWen-Ting Lo, Hassane Belabed, Murat Kücükdisli, et al.
The Biochemical Journal|November 1, 2024
ATP-competitive inhibitors of PI3K enzymes demonstrate an isoform selective dual action by controlling membrane bindingGrace Q Gong, Glenn R Masson, Woo-Jeong Lee, et al.
Nature|August 6, 2013
Vesicular and non-vesicular transport feed distinct glycosylation pathways in the GolgiGiovanni D'Angelo, Takefumi Uemura, Chia-Chen Chuang, et al.
Science Signaling|December 6, 2012
G protein-coupled receptor-mediated activation of p110β by Gβγ is required for cellular transformation and invasivenessHashem A Dbouk, Oscar Vadas, Aliaksei Shymanets, et al.
Nature Communications|September 27, 2019
Human PI3Kγ deficiency and its microbiota-dependent mouse model reveal immunodeficiency and tissue immunopathologyAndrew J Takeda, Timothy J Maher, Yu Zhang, et al.
Pageof 13